Foundation Fighting Blindness Retinal Degeneration Fund 4

What Happened The reporting entity, Foundation Fighting Blindness Retinal Degeneration Fund (RDF) — reported as a director-level reporting person — sold 1,700,000 shares of Opus Genetics, Inc. (ticker: IRD) in an open market or private sale on May 18, 2026. The shares were disposed at $4.35 per share for a total transaction value of $7,395,000. This was a sale (transaction code S); the filing does not state a plan or reason for the disposition.

Key Details

• Transaction date and price: 2026-05-18, sold 1,700,000 shares at $4.35 each.
• Total value: $7,395,000.
• Method: Reported as "open market or private sale" (S).
• Shares owned after transaction: Not specified in the Form 4 filing.
• Footnote: Foundation Fighting Blindness, Inc. (FFB) is the sole member of RDF and may be deemed to beneficially own RDF’s securities; RDF’s board makes voting/investment decisions subject to certain FFB approval rights (see F1).
• Remarks: The filing notes RDF is reported as a director by deputization — Adrienne Graves, PhD and Jean Bennett, MD, PhD were appointed to Opus’s board; Dr. Graves chairs RDF’s board and sits on FFB’s board, and Dr. Bennett is on RDF’s board.
• Timeliness: Filing date 2026-05-20 for a 2026-05-18 transaction — no late filing indicated.

Context Sales by institutional holders or funds are common and do not, by themselves, indicate management sentiment about the company; the Form 4 does not disclose a 10b5-1 plan, tax withholding, or other reason for the sale. RDF is an institutional/charitable-related holder (with FFB as sole member), not an individual executive, which matters for how investors interpret the transaction.